Clinical Trial Detail

NCT ID NCT03409614
Title REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Regeneron Pharmaceuticals
Indications

non-small cell lung carcinoma

Therapies

Ipilimumab + REGN2810

Cemiplimab

Age Groups: senior adult

Additional content available in CKB BOOST